Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

Current factor VIII (FVIII) products display a half-life (t(1/2)) of ∼ 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A. rFVIIIFc is a recombinant fusion protein composed of a single molecule of FVIII covalently linked to the Fc domain...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Powell, Jerry S., Josephson, Neil C., Quon, Doris, Ragni, Margaret V., Cheng, Gregory, Li, Ella, Jiang, Haiyan, Li, Lian, Dumont, Jennifer A., Goyal, Jaya, Zhang, Xin, Sommer, Jurg, McCue, Justin, Barbetti, Margaret, Luk, Alvin, Pierce, Glenn F.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2012
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646317/
https://ncbi.nlm.nih.gov/pubmed/22223821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-09-382846
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker